Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies

Journal of the National Cancer Institute

Volumn 94, Issue 19, 2002, Pages 1484-1493

  Jayson, Gordon C ^a,b   Zweit, Jamal ^c   Jackson, Alan ^d   Mulatero, Clive ^a   Julyan, Peter ^b   Ranson, Malcolm ^a   Broughton, Lynn ^a   Wagstaff, John ^e   Hakannson, Leif ^f   Groenewegen, Gerard ^g   Bailey, John ^c   Smith, Nigel ^c   Hastings, David ^b   Lawrance, Jeremy ^b   Haroon, Hamied ^d   Ward, Tim ^c   McGown, Alan T ^c   Tang, Meina ^h   Levitt, Dan ^h   Marreaud, Sandrine ⁱ   Lehmann, Frederic F ⁱ   Herold, Manfred ^j   Zwierzina, Heinz ^j   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h PROTEIN DESIGN LABS INC   (United States)

ⁱ EORTC DATA CENTER   (Belgium)

^j UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOKINE; IODINE 124; MONOCLONAL ANTIBODY; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADULT; ANGIOGENESIS; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PENETRATION; DRUG TOLERABILITY; DRUG UPTAKE; FIRST PASS EFFECT; HUMAN; LARYNX CANCER; MELANOMA; METHODOLOGY; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0037009827     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.19.1484     Document Type: Article

References (28)

1. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
2. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
3. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase lb trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-6.
4. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 2000;6:4848-58.
5. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-60.
6. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000; 60:970-5.
7. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000;60:4819-24.
8. Davidoff AM, Leary MA, Ng CY, Vanin EF. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk- 1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001;36:30-6.
9. Yang JC, Haworth L, Steinberg SM, Rosenberg SA, Novotny W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer [abstract No, 15]. Proc ASCO 2002;21.
10. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe 0, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 2002;20:1446-8.
11. Asano M, Yukita A, Suzuki H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 1999;90:93-100.
12. Herbst RS, Tran HT, Mullani NA, Charnsangavej C, Madden TL, Hess KR, et al. Phase I clinical trial of recombinant human endostatin (rHE) in patients (Pts) with solid tumors: pharmacokinetic (PK), safety and efficacy analysis using surrogate endpoints of tissue and radiologic response [abstract No. 91. Proc ASCO 2001;20.
13. Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998-,17:185-90.
14. Queen C, Schneider WP, Selick HE, Payne PW, Landolfl. NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989;86:10029-33.
15. Levitt M. Molecular dynamics of native protein. J Mol Biol 1983;168: 595-620.
16. Sauer PW, Burky JE, Wesson MC, Sternard HD, Qu L. A high-yielding, generic fed-batch cell culture process for production of recombinant anti-bodies. Biotechnol Bioeng 2000;67:585-97.
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
19. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. Measurements of the true affinity constapt in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 1985; 77:305-19.
20. Hudson H, Larkin R. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13:601-9.
21. Tofts PS. Modeling tracer kinetics dynamic, Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
22. Jackson A, Haroon H, Zhu XP, Li KL, Thacker NA, Jayson G. Breath hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first pass leakage profile model. NMR Biomed 2002;15:164-73.
23. Li KL, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 2000;12:347-57.
24. Zhu XP, Li KL, Kamaly-Asl ID, Checkley DR, Tessier JJ, Waterton JC, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined TI and T2*contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000; 11:575-85.
25. Wagner JG. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 1976;4:443-67.
26. Gibaldi M, Perrier D. Pharmacokinetics. 1st ed. New York (NY): Marcel Dekker; 1982.
27. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995;86:2488-93.
28. Thomas A, Morgan B, Drevs J, Jivan A, Buchert M, Horsfield M, et al. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging of 2 Phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer [abstract No. 279]. Proc ASCO 2001;20.